Comment on: "Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide"...Li H-Y, Cheriyan J, Chan T-K, et al. American Journal of Cardiovascular Drugs. 2026;26(1):107-120.
This article focuses on a trial sequential analysis (TSA) conducted to evaluate the robustness of colchicine’s effect on major adverse cardiovascular events (MACE) in cardiovascular disease (CVD) populations, based on a prior meta-analysis of 14 randomized controlled trials. The TSA found that while...
| Published in: | American Journal of Cardiovascular Drugs Vol. 26; no. 4; pp. 507 - 510 |
|---|---|
| Main Authors: | , , , |
| Format: | commentary letter tables/charts Journal Article |
| Published: |
Springer Nature
Jul2026
|
| Online Access: | View this record in EBSCOhost |
| Summary: | This article focuses on a trial sequential analysis (TSA) conducted to evaluate the robustness of colchicine’s effect on major adverse cardiovascular events (MACE) in cardiovascular disease (CVD) populations, based on a prior meta-analysis of 14 randomized controlled trials. The TSA found that while colchicine’s benefit in the overall CVD population is statistically robust, the evidence for its effect in the acute atherothrombotic CVD subgroup remains inconclusive due to insufficient information size and potential type I error. These results highlight the need for cautious interpretation of subgroup findings in cumulative meta-analyses and suggest that clinical decisions should prioritize evidence from the broader CVD population until further adequately powered trials clarify colchicine’s efficacy in specific subgroups. |
|---|